Drugs / GSK3888550A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03674177 | Oct 2018 → Apr 2019 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-10-21 | GlaxoSmithKline | Results GSK presents positive clinical data on maternal and older adults RSV candidate vaccines gsk.com ↗
GSK today announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunisation (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in Phase I/II clinical studies. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-21 | GlaxoSmithKline | GSK presents positive clinical data on maternal and older adults RSV candidate vaccines gsk.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3888550A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03674177 ↗ |
| Modality | Vaccine | “investigational RSV maternal vaccine (GSK3888550A)” NCT03674177 ↗ |
| Route | Intramuscular | “administered as a single intramuscular injection (IM)” NCT03674177 ↗ |